Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ME2 | P23368 | 2/20 | 0.48 |
| ▸ | ME1 | P48163 | 2/20 | 0.48 |
| ▸ | ME3 | Q16798 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | PANK3 | Q9H999 | 8/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3331511 | 0.86 | HPGD (0.50) | ME2ME1ME3HPGDNPSR1 | |
| SCHEMBL3334079 | 0.86 | KDM4E (0.58) | ME2ME1ME3HPGDNPSR1 | |
| SCHEMBL3331527 | 0.83 | MEN1 (0.55) | ME2ME1ME3HPGDNPSR1 | |
| SCHEMBL3338157 | 0.82 | KDM4E (0.58) | HPGDNPSR1HSD17B10L3MBTL1PANK3 | |
| SCHEMBL3334455 | 0.81 | TRPA1 (0.55) | ME2ME1ME3HPGDNPSR1 | |
| SCHEMBL3335793 | 0.79 | ME2 (0.47) | ME2ME1ME3HPGDNPSR1 | |
| SCHEMBL3334743 | 0.79 | THRB (0.52) | ME2ME1ME3HPGDNPSR1 | |
| SCHEMBL3337346 | 0.78 | BRS3 (0.47) | ME2ME1ME3HPGDNPSR1 | |
| SCHEMBL3336642 | 0.78 | HSD17B10 (0.50) | ME2ME1ME3HPGDNPSR1 | |
| SCHEMBL3332171 | 0.78 | HRH3 (0.58) | ME2ME1ME3HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | claimed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | GRM5, GRM1, GRM2 | ME2 3420/4885ME1 2744/4885ME3 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.